Veracyte, Inc.
VCYT
$32.13
$1.203.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 517.15M | 495.14M | 479.13M | 463.39M | 445.76M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 517.15M | 495.14M | 479.13M | 463.39M | 445.76M |
| Cost of Revenue | 150.27M | 151.86M | 147.33M | 143.21M | 142.29M |
| Gross Profit | 366.88M | 343.28M | 331.80M | 320.19M | 303.48M |
| SG&A Expenses | 212.82M | 207.26M | 204.25M | 200.79M | 197.66M |
| Depreciation & Amortization | 13.15M | 13.43M | 13.90M | 14.40M | 14.85M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 447.06M | 441.81M | 436.33M | 429.45M | 424.09M |
| Operating Income | 70.09M | 53.33M | 42.80M | 33.95M | 21.68M |
| Income Before Tax | 68.20M | 31.01M | 28.97M | 35.08M | 25.74M |
| Income Tax Expenses | 1.85M | 693.00K | 2.63M | 2.03M | 1.61M |
| Earnings from Continuing Operations | 66.35 | 30.32 | 26.34 | 33.05 | 24.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 66.35M | 30.32M | 26.34M | 33.05M | 24.14M |
| EBIT | 70.09M | 53.33M | 42.80M | 33.95M | 21.68M |
| EBITDA | 91.50M | 75.70M | 65.78M | 57.18M | 45.14M |
| EPS Basic | 0.84 | 0.39 | 0.34 | 0.43 | 0.31 |
| Normalized Basic EPS | 0.64 | 0.53 | 0.47 | 0.37 | 0.25 |
| EPS Diluted | 0.82 | 0.38 | 0.33 | 0.41 | 0.30 |
| Normalized Diluted EPS | 0.63 | 0.52 | 0.46 | 0.36 | 0.25 |
| Average Basic Shares Outstanding | 314.32M | 312.75M | 311.04M | 309.19M | 305.92M |
| Average Diluted Shares Outstanding | 319.53M | 318.04M | 316.82M | 315.59M | 310.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |